CN104745681A - 多元基因组合物及其用途 - Google Patents
多元基因组合物及其用途 Download PDFInfo
- Publication number
- CN104745681A CN104745681A CN201410389862.8A CN201410389862A CN104745681A CN 104745681 A CN104745681 A CN 104745681A CN 201410389862 A CN201410389862 A CN 201410389862A CN 104745681 A CN104745681 A CN 104745681A
- Authority
- CN
- China
- Prior art keywords
- rnf180
- cancer
- septin9
- dna
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 101000667651 Homo sapiens E3 ubiquitin-protein ligase RNF180 Proteins 0.000 claims abstract description 121
- 101150042012 SEPTIN9 gene Proteins 0.000 claims abstract description 121
- 102100039798 E3 ubiquitin-protein ligase RNF180 Human genes 0.000 claims abstract description 120
- 102000012060 Septin 9 Human genes 0.000 claims abstract description 116
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 68
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 65
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 65
- 230000011987 methylation Effects 0.000 claims abstract description 54
- 238000007069 methylation reaction Methods 0.000 claims abstract description 54
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 239000012634 fragment Substances 0.000 claims abstract description 29
- 230000005856 abnormality Effects 0.000 claims abstract description 23
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 103
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 84
- 201000000498 stomach carcinoma Diseases 0.000 claims description 71
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 201000011510 cancer Diseases 0.000 claims description 54
- 238000012360 testing method Methods 0.000 claims description 52
- 125000003729 nucleotide group Chemical group 0.000 claims description 48
- 239000002773 nucleotide Substances 0.000 claims description 45
- 101150032258 RNF180 gene Proteins 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 30
- 230000000295 complement effect Effects 0.000 claims description 30
- 230000004663 cell proliferation Effects 0.000 claims description 23
- 230000001568 sexual effect Effects 0.000 claims description 21
- 210000002381 plasma Anatomy 0.000 claims description 19
- 229940104302 cytosine Drugs 0.000 claims description 18
- 108091034117 Oligonucleotide Proteins 0.000 claims description 15
- 239000012472 biological sample Substances 0.000 claims description 15
- 230000007067 DNA methylation Effects 0.000 claims description 14
- 238000001574 biopsy Methods 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- GRWZHXKQBITJKP-UHFFFAOYSA-N dithionous acid Chemical group OS(=O)S(O)=O GRWZHXKQBITJKP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 238000003556 assay Methods 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 239000002689 soil Substances 0.000 claims description 6
- 210000003677 hemocyte Anatomy 0.000 claims description 5
- 229940000351 hemocyte Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 230000000112 colonic effect Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 abstract description 52
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 239000000523 sample Substances 0.000 description 186
- 108020004414 DNA Proteins 0.000 description 135
- 239000013615 primer Substances 0.000 description 122
- 238000003752 polymerase chain reaction Methods 0.000 description 110
- 238000000034 method Methods 0.000 description 65
- 230000003321 amplification Effects 0.000 description 42
- 238000003199 nucleic acid amplification method Methods 0.000 description 42
- 239000002987 primer (paints) Substances 0.000 description 42
- 230000035945 sensitivity Effects 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 33
- 206010017758 gastric cancer Diseases 0.000 description 32
- 201000011549 stomach cancer Diseases 0.000 description 31
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 25
- 238000009396 hybridization Methods 0.000 description 23
- 230000008569 process Effects 0.000 description 21
- 102000007469 Actins Human genes 0.000 description 20
- 108010085238 Actins Proteins 0.000 description 20
- 239000000463 material Substances 0.000 description 19
- 230000008859 change Effects 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 17
- 208000032839 leukemia Diseases 0.000 description 16
- 208000007882 Gastritis Diseases 0.000 description 15
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 14
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 14
- 201000005202 lung cancer Diseases 0.000 description 14
- 208000020816 lung neoplasm Diseases 0.000 description 14
- 108091093088 Amplicon Proteins 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 238000000137 annealing Methods 0.000 description 12
- 230000004087 circulation Effects 0.000 description 12
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 201000002313 intestinal cancer Diseases 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000002203 pretreatment Methods 0.000 description 11
- 238000012408 PCR amplification Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 238000013016 damping Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 description 7
- 210000001541 thymus gland Anatomy 0.000 description 7
- 239000012807 PCR reagent Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 208000023652 chronic gastritis Diseases 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 5
- 108050004875 Septin Proteins 0.000 description 5
- 108050002584 Septin 9 Proteins 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- -1 methane amide Chemical class 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000001035 methylating effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108091029523 CpG island Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 108091092584 GDNA Proteins 0.000 description 3
- 102000015602 Septin Human genes 0.000 description 3
- 229930003756 Vitamin B7 Natural products 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011735 vitamin B7 Substances 0.000 description 3
- 235000011912 vitamin B7 Nutrition 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011897 real-time detection Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DVOOXRTYGGLORL-VKHMYHEASA-N (2r)-2-(methylamino)-3-sulfanylpropanoic acid Chemical compound CN[C@@H](CS)C(O)=O DVOOXRTYGGLORL-VKHMYHEASA-N 0.000 description 1
- BRRSNXCXLSVPFC-UHFFFAOYSA-N 2,3,4-Trihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1O BRRSNXCXLSVPFC-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000632056 Homo sapiens Septin-9 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 101100409186 Mus musculus Prg4 gene Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101000864964 Rattus norvegicus Septin-9 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100028024 Septin-9 Human genes 0.000 description 1
- 101710183568 Serine/threonine-protein kinase PknK Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000011365 genetic imprinting Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
癌症样本 | Ct RNF180 | Ct Septin9 | 关联 | 诊断 |
6/亚/男/63 | / | 38.19 | 互补 | 阳性 |
35/亚/男/58 | 37.62 | / | 互补 | 阳性 |
36/亚/女/53 | 34.46 | 38.34 | 阳性 | |
39/亚/女/58 | 31.84 | 34.51 | 阳性 | |
41/亚/男/53 | 33.28 | 38.67 | 阳性 | |
42/亚/女/58 | 36.96 | / | 互补 | 阳性 |
43/亚/女/56 | 32.90 | 36.03 | 阳性 | |
59/亚/男/57 | 34.56 | 38.00 | 阳性 | |
61/亚/男/69 | 34.71 | / | 互补 | 阳性 |
68/亚/女/49 | 35.15 | No Ct | 互补 | 阳性 |
阳性率 | 90% | 70% | 阳性 |
健康人血浆 | Ct RNF180 | Ct Septin9 |
H1/亚/男/30 | / | / |
H2/亚/女/27 | 36.45 | / |
H3/亚/男/24 | / | / |
H4/亚/女/45 | / | / |
H5/亚/男/35 | / | / |
H6/亚/男女/32 | / | / |
特异性 | 83% | 100% |
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410389862.8A CN104745681B (zh) | 2014-08-08 | 2014-08-08 | 多元基因组合物及其用途 |
PCT/CN2015/086369 WO2016019900A1 (zh) | 2014-08-08 | 2015-08-07 | 多元基因组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410389862.8A CN104745681B (zh) | 2014-08-08 | 2014-08-08 | 多元基因组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104745681A true CN104745681A (zh) | 2015-07-01 |
CN104745681B CN104745681B (zh) | 2018-11-06 |
Family
ID=53585931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410389862.8A Active CN104745681B (zh) | 2014-08-08 | 2014-08-08 | 多元基因组合物及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104745681B (zh) |
WO (1) | WO2016019900A1 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016019900A1 (zh) * | 2014-08-08 | 2016-02-11 | 博尔诚(北京)科技有限公司 | 多元基因组合物及其用途 |
CN106834426A (zh) * | 2015-12-04 | 2017-06-13 | 博尔诚(北京)科技有限公司 | 用于检测胰腺癌的组合物及其用途 |
CN107326065A (zh) * | 2016-04-29 | 2017-11-07 | 博尔诚(北京)科技有限公司 | 一种基因标识物的筛选方法及其应用 |
CN107475366A (zh) * | 2017-07-03 | 2017-12-15 | 博尔诚(北京)科技有限公司 | 一种用于检测疾病的组合物及其试剂盒和用途 |
CN107727865A (zh) * | 2016-08-11 | 2018-02-23 | 博尔诚(北京)科技有限公司 | 肿瘤标志物的系统性检测方法及其应用 |
CN107904313A (zh) * | 2017-12-29 | 2018-04-13 | 韩林志 | 用于胃癌相关基因Reprimo、RNF180甲基化检测的引物对、试剂盒及方法 |
CN108220428A (zh) * | 2016-12-12 | 2018-06-29 | 博尔诚(北京)科技有限公司 | 用于检测胃癌的组合物及其试剂盒和用途 |
WO2019144275A1 (zh) * | 2018-01-23 | 2019-08-01 | 北京艾克伦医疗科技有限公司 | 鉴定肺癌状态的方法和试剂盒 |
WO2020019269A1 (zh) * | 2018-07-26 | 2020-01-30 | 北京艾克伦医疗科技有限公司 | 鉴定胃癌状态的方法和试剂盒 |
CN111549129A (zh) * | 2020-03-30 | 2020-08-18 | 宁波美康盛德医学检验所有限公司 | 用于检测胃癌的试剂盒及其应用 |
CN118064579A (zh) * | 2024-01-23 | 2024-05-24 | 瑞博奥(广州)生物科技股份有限公司 | 一种检测RNF180和Septin9基因甲基化的试剂盒 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109055552A (zh) * | 2018-08-23 | 2018-12-21 | 北京迈基诺基因科技股份有限公司 | 检测Septin9基因启动子是否甲基化的方法及其专用成套试剂 |
CN111826441A (zh) * | 2019-04-23 | 2020-10-27 | 博尔诚(北京)科技有限公司 | 用于体外检测消化道五癌的体系,在该体系中使用的组合物,以及包含该组合物的试剂盒 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101160411A (zh) * | 2005-04-15 | 2008-04-09 | Epi基因组股份公司 | 分析细胞增殖性病症的方法和核酸 |
US20110151443A1 (en) * | 2009-12-23 | 2011-06-23 | The Chinese University of Hong Kong Room 328, Pi Ch'iu Building | Marker for gastric cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104745575B (zh) * | 2014-08-08 | 2019-03-12 | 博诚研究中心 | 用于检测细胞增殖性异常或疾病程度分级的基因组合物及其用途 |
CN104745681B (zh) * | 2014-08-08 | 2018-11-06 | 博尔诚(北京)科技有限公司 | 多元基因组合物及其用途 |
-
2014
- 2014-08-08 CN CN201410389862.8A patent/CN104745681B/zh active Active
-
2015
- 2015-08-07 WO PCT/CN2015/086369 patent/WO2016019900A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101160411A (zh) * | 2005-04-15 | 2008-04-09 | Epi基因组股份公司 | 分析细胞增殖性病症的方法和核酸 |
US20110151443A1 (en) * | 2009-12-23 | 2011-06-23 | The Chinese University of Hong Kong Room 328, Pi Ch'iu Building | Marker for gastric cancer |
Non-Patent Citations (3)
Title |
---|
HUI-MIN CHEN等: "Epigenetic Biomarkers for the Early Detection of Gastrointestinal Cancer", 《GASTROINTEST TUMORS》 * |
JIAQIU LI等: "Epigenetic Biomarkers: Potential Applications in Gastrointestinal Cancers", 《ISRN GASTROENTEROLOGY》 * |
张意琴等: "胃癌组织septin 9 基因甲基化及其临床意义研究", 《中国卫生检验杂志》 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016019900A1 (zh) * | 2014-08-08 | 2016-02-11 | 博尔诚(北京)科技有限公司 | 多元基因组合物及其用途 |
CN106834426A (zh) * | 2015-12-04 | 2017-06-13 | 博尔诚(北京)科技有限公司 | 用于检测胰腺癌的组合物及其用途 |
CN106834426B (zh) * | 2015-12-04 | 2022-07-29 | 博尔诚(北京)科技有限公司 | 用于检测胰腺癌的组合物及其用途 |
CN107326065B (zh) * | 2016-04-29 | 2022-07-29 | 博尔诚(北京)科技有限公司 | 一种基因标识物的筛选方法及其应用 |
CN107326065A (zh) * | 2016-04-29 | 2017-11-07 | 博尔诚(北京)科技有限公司 | 一种基因标识物的筛选方法及其应用 |
CN107727865A (zh) * | 2016-08-11 | 2018-02-23 | 博尔诚(北京)科技有限公司 | 肿瘤标志物的系统性检测方法及其应用 |
CN108220428A (zh) * | 2016-12-12 | 2018-06-29 | 博尔诚(北京)科技有限公司 | 用于检测胃癌的组合物及其试剂盒和用途 |
CN108220428B (zh) * | 2016-12-12 | 2022-10-28 | 博尔诚(北京)科技有限公司 | 用于检测胃癌的组合物及其试剂盒和用途 |
CN107475366B (zh) * | 2017-07-03 | 2020-04-28 | 博尔诚(北京)科技有限公司 | 一种用于检测疾病的组合物及其试剂盒和用途 |
CN107475366A (zh) * | 2017-07-03 | 2017-12-15 | 博尔诚(北京)科技有限公司 | 一种用于检测疾病的组合物及其试剂盒和用途 |
CN107904313A (zh) * | 2017-12-29 | 2018-04-13 | 韩林志 | 用于胃癌相关基因Reprimo、RNF180甲基化检测的引物对、试剂盒及方法 |
WO2019144275A1 (zh) * | 2018-01-23 | 2019-08-01 | 北京艾克伦医疗科技有限公司 | 鉴定肺癌状态的方法和试剂盒 |
US12018333B2 (en) | 2018-01-23 | 2024-06-25 | Excellen Medical | Method and kit for identifying lung cancer status |
WO2020019269A1 (zh) * | 2018-07-26 | 2020-01-30 | 北京艾克伦医疗科技有限公司 | 鉴定胃癌状态的方法和试剂盒 |
CN111549129A (zh) * | 2020-03-30 | 2020-08-18 | 宁波美康盛德医学检验所有限公司 | 用于检测胃癌的试剂盒及其应用 |
CN111549129B (zh) * | 2020-03-30 | 2023-08-29 | 宁波美康盛德医学检验所有限公司 | 用于检测胃癌的试剂盒及其应用 |
CN118064579A (zh) * | 2024-01-23 | 2024-05-24 | 瑞博奥(广州)生物科技股份有限公司 | 一种检测RNF180和Septin9基因甲基化的试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN104745681B (zh) | 2018-11-06 |
WO2016019900A1 (zh) | 2016-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11840739B2 (en) | Gene composition for detecting cell proliferative abnormality or grading disease degree and use thereof | |
CN104745681A (zh) | 多元基因组合物及其用途 | |
CN105925681A (zh) | 一种用于肺癌筛查的组合物及其应用 | |
CN106834426B (zh) | 用于检测胰腺癌的组合物及其用途 | |
US20230366034A1 (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
KR20120099630A (ko) | Braf 변이의 검출을 위해 유용한 방법, 프라이머, 프로브 및 키트 | |
KR20080004408A (ko) | 메틸 가변 부위의 메틸화를 측정하여 암의 유무를 판별하는방법 | |
CN106676191B (zh) | 一种用于结肠腺癌的分子标志物 | |
JP2024020392A (ja) | 特定の遺伝子のcpgメチル化変化を利用した肝癌診断用組成物およびその使用 | |
EP2780476B1 (en) | Methods for diagnosis and/or prognosis of gynecological cancer | |
CN113355415B (zh) | 用于食管癌诊断或辅助诊断的检测试剂及试剂盒 | |
Langevin et al. | Novel DNA methylation targets in oral rinse samples predict survival of patients with oral squamous cell carcinoma | |
CN107400704A (zh) | 一种用于乳腺癌筛查的组合物及其应用 | |
EP3368684B1 (en) | Biomarker for breast cancer | |
JP5865241B2 (ja) | 肉腫の予後分子署名およびその使用 | |
US20150329911A1 (en) | Nucleic acid biomarkers for prostate cancer | |
EP2450455A1 (en) | Method for determining presence or absence of epithelial cancer-origin cell in biological sample, and molecular marker and kit therefor | |
US11542559B2 (en) | Methylation-based biomarkers in breast cancer screening, diagnosis, or prognosis | |
US9096904B2 (en) | Method for determining lymph node metastasis in cancer or risk thereof and rapid determination kit for the same | |
Asayut et al. | RHEB methylation in white blood cell, a novel candidate marker for breast cancer screening. | |
JP6551656B2 (ja) | 卵巣癌に関する情報の取得方法、ならびに卵巣癌に関する情報を取得するためのマーカーおよび卵巣癌検出用キット | |
CN117004722A (zh) | 用于检测肺癌的组合物及其用途 | |
CN117327796A (zh) | 用于检测尿路上皮癌的组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 100176, No. 7, North Yongchang Road, Beijing economic and Technological Development Zone, Beijing, Daxing District, 4 Applicant after: Biochain (Beijing) Science & Technology Co., Ltd. Applicant after: BIOCHAIN INSTITUTE, INC. Address before: 100176, No. 7, North Yongchang Road, Beijing economic and Technological Development Zone, Beijing, Daxing District, 4 Applicant before: Biochain (Beijing) Science & Technology Co., Ltd. Applicant before: The sincere research company of Bo Er |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: BIOCHAIN RESEARCH COMPANY TO: BOCHENG RESEARCH CENTER |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200728 Address after: 10 / F, building 3, yard 18, Hongda South Road, Daxing District, Beijing Co-patentee after: BIOCHAIN INSTITUTE, Inc. Patentee after: BIOCHAIN (BEIJING) SCIENCE & TECHNOLOGY Co.,Ltd. Co-patentee after: PEOPLE'S LIBERATION ARMY AIR FORCE MILITARY MEDICAL University Address before: 100176, No. 7, North Yongchang Road, Beijing economic and Technological Development Zone, Beijing, Daxing District, 4 Co-patentee before: BIOCHAIN INSTITUTE, Inc. Patentee before: BIOCHAIN (BEIJING) SCIENCE & TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20211009 Address after: 100176 10th floor, building 3, No.18 yard, Hongda South Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing Patentee after: BIOCHAIN (BEIJING) SCIENCE & TECHNOLOGY Co.,Ltd. Patentee after: Air Force Medical University Address before: 100176 10th floor, building 3, No.18 yard, Hongda South Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing Patentee before: BIOCHAIN (BEIJING) SCIENCE & TECHNOLOGY Co.,Ltd. Patentee before: BIOCHAIN INSTITUTE, Inc. Patentee before: Air Force Medical University |
|
TR01 | Transfer of patent right |